Ananda Pharma

Ananda Pharma (formerly Ananda Developments) is a UK-based biopharmaceutical company developing cannabidiol (CBD)-based medicines for complex chronic inflammatory pain conditions. The company is listed on AQSE (AQSE: ANA) and focuses on regulatory-approved drug development. It operates two Phase 2 randomised controlled trials, funded by non-dilutive grants, for chemotherapy-induced peripheral neuropathy (CIPN) and endometriosis-associated pain using its patent-pending MRX1 formulation. Pre-clinical findings for heart failure with preserved ejection fraction (HFpEF) have also been announced. Ananda's core assets include patent-pending MRX cannabinoid formulations and a genetic stabilisation program for consistent pharmaceutical-grade cannabis cultivation. The company has also launched unlicensed cannabinoid medicines (MRX1 and MRX2) for near-term revenue generation.